CQN-THE-GENEVA-ASSOC.
6.3.2017 16:45:15 CET | Business Wire | Press release
First paragraph, second sentence of release, the date should be 9th March 2017 instead of 8th March 2017.
The corrected release reads:
THE GENEVA ASSOCIATION: HOW WILL RISK MODELLING SHAPE THE FUTURE OF RISK TRANSFER? GLOBAL EXPERTS LEAD THE WAY
Leading think tank of the international insurance industry, The Geneva Association, welcomes top international experts to discuss and explore the issue – “How Will Risk Modelling Shape the Future of Risk Transfer?” This scientific seminar is co-organised with the SCOR Foundation and hosted at the SCOR Paris headquarters on 9th March 2017. It will inform a ground-breaking research report by The Geneva Association’s Extreme Events and Climate Risk Research Programme, publishing in June 2017.
The last three and a half decades have witnessed a general trend of rising economic losses associated with extreme events. This is due to multiple factors, including increased concentration of people and assets in exposed areas such as coastal regions, poor development planning and related practices, highly sophisticated but vulnerable global production processes and the increasing severity and frequency of extreme weather-related events linked to a changing climate.
Risk analysis is the foundation for informed decision-making, increasing the understanding of the characteristics of risk, supporting risk pricing, and evaluating cost–benefits of various risk management strategies. In the mid-1980s and early 1990s, a number of major catastrophes in North America and Europe led to unprecedented high losses, resulting in insolvencies and/or bankruptcies in the insurance sector, and pointing to the need for a more rigorous and quantifiable approach to assessing and underwriting risks.
The development and utilization of catastrophe risk models (cat models) over the last 25 years has revolutionized the (re)insurance industry’s approach to pricing, underwriting and managing their complex risk portfolios. Beyond the insurance sector, the international development community has also adopted these models to help governments better understand risk and make risk-based decisions, helping improve disaster and climate risk management decisions.
The seminar brings together leading international experts from the (re)insurance industry, risk modelling community, international organizations, international donors, governments and the scientific community to share experiences and explore opportunities for strengthened cooperation and partnerships. The programme will examine the following critical issues:
(i) Enhancing current cat models – building on lessons learned from their development and utilization over the last 25 years;
(ii) Finding effective pathways to expand risk information and cat risk modelling tools to support public-sector decisions; and,
(iii) Harnessing the latest scientific and technological developments for a new generation of forward-looking risk models.
Dr. Maryam Golnaraghi, Director of the Extreme Events and Climate Risks Research Programme at The Geneva Association, said: “As one of its top priorities, The Geneva Association is convening a diverse group of leading experts in the industry, cat modelling, and various areas of science and technology to explore how risk modelling can shape the future of risk transfer around the world. Specifically, we are not only exploring opportunities to enhance current cat modelling approaches, but also opportunities for harnessing scientific and technological advancements in areas such as environmental surveillance, climate monitoring and forecasting, engineering, big data, and artificial intelligence for development of the new generation of systems-based risk models that can innovate risk transfer.”
Anna Maria D’Hulster, Secretary General of the Geneva Association said, “The insurance industry has deep risk knowledge and is working at the forefront of risk assessment, risk pricing and risk transfer. Public-private partnerships could be instrumental in helping the public sector in developing risk-informed preventive measures and risk transfer programmes that help government, businesses and individuals with managing their risks.”
ENDS
Notes to Editors
The Geneva Association is the leading international insurance think tank for strategically important insurance and risk management issues. It is a unique platform for dialogue between leaders of the insurance industry and key decision-makers at the international and national levels to evidence the important social and economic role of the insurance industry.
The Geneva Association identifies fundamental trends and strategic issues where insurance plays a substantial role or which influence the insurance sector. Through the development of research programmes, regular publications and the organisation of international meetings, The Geneva Association serves as a catalyst for progress in the understanding of risk and insurance matters and acts as an information creator and disseminator.
The Geneva Association membership comprises a statutory maximum of 90 chief executive officers (CEOs) from the world’s top insurance and reinsurance companies. It organises international expert networks and manages discussion platforms for senior insurance executives and specialists as well as policy-makers, regulators and multilateral organisations.
Established in 1973, The Geneva Association, officially the “International Association for the Study of Insurance Economics”, is based in Zurich, Switzerland and is a non-profit organisation funded by its membership.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170306005789/en/
Contact:
The Geneva Association
Isabel Barratt
Communications
Manager
+41 44 200 49 96
isabel_barratt@genevaassociation.org
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press release
Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety profile in children ages 6 through 17 yearsFirst pediatric clinical trial builds on 5 prior adult BPZE1 clinical studiesDemonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individualsNo interference observed when BPZE1 co-administered with diphtheria and tetanus antigens ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The stu
NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 12:45:00 CEST | Press release
New AI and automation capabilities help retailers close execution gaps and scale merchandising decisions across every store. NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time buil
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.10.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity awards to the ten newly hired non-executive employees were granted on October 1, 2026 and consisted of options to purchase an aggregate of 97,100 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 46,200 shares. These options have an exercise price per share equal to $11.95, the closing price of the Company’s American De
Global Health Leaders to Convene at Abu Dhabi Future Health Summit 20262.10.2026 12:24:00 CEST | Press release
Abu Dhabi Future Health Summit will convene leaders across healthcare, science, technology, policy, and investment from 20-22October at ADNEC Centre Abu DhabiUnder the 2026 theme ‘To Sense is to Predict’, the Future Health Summit will examine how greater health insight can enable earlier intervention and better outcomesAstraZeneca CEO Sir Pascal Soriot, Isomorphic Labs President Mr. Max Jaderberg, Amref Health Africa Group CEO Dr. Githinji Gitahi, and Health Ministers from Kosovo, Montenegro, Serbia and Colombia are among more than 130 Forum speakers, with participation expected from 100 countries Global leaders across healthcare, science, technology, policy, and investment will convene at the Abu Dhabi Future Health Summit from 20 to 22 October 2026 to examine how health systems can better anticipate risk and enable earlier intervention as advances in AI, genomics, diagnostics, and health data create new possibilities for understanding health risks earlier. This press release features
Venture Global and ConocoPhillips Announce 20-Year LNG Sales and Purchase Agreement1.10.2026 22:30:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and ConocoPhillips (NYSE: COP) announced a new, long-term Sales and Purchase Agreement (SPA) for liquefied natural gas (LNG). Under the SPA, ConocoPhillips will buy 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. "Venture Global is proud to welcome ConocoPhillips, one of the world's leading energy companies, as a long-term partner," said Venture Global CEO Mike Sabel. "This agreement reflects continued market confidence in our proven ability to deliver reliable, low-cost U.S. LNG quickly and at scale. We look forward to supporting ConocoPhillips' growing global LNG portfolio for decades to come." About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
